三维彩色多普勒血流显像超声对膀胱肿瘤的诊断价值

目的探讨分析三维彩色多普勒血流显像超声(3D-CDFI)对膀胱肿瘤诊断的临床价值。方法选取我院2012年1月~2014年2月收治的43例膀胱占位性病变患者的52个占位病灶，对其二维超声、彩色多普勒血流显像（CDFI）、3D-CDFI检查诊断结果与膀胱镜及病理诊断结果相比较，分析3D-CDFI对膀胱肿瘤诊断的临床价值。结果膀胱镜检及病理诊断本组52个占位病灶中48个为膀胱肿瘤，恶性者占93.75%（45/48），良性者占6.25%（3/48）；4个为非膀胱肿瘤（膀胱内凝血块3个，膀胱子宫内膜异位灶1个）。超声对膀胱占位性病灶诊断符合率三维超声96.15%（50/52）明显高于二维超声85.69%（43/52），两组比较P<0.05，差异具有统计学意义。膀胱肿瘤内彩色多普勒血流显示率3D-CDFI 85.25%（39/48）明显高于CDFI 62.50%（30/48），两组比较P<0.05，差异具有统计学意义。3D-CDFI超声分期和病理分期的符合率显著优于二维超声，两组比较P<0.05，差异具有统计学意义。结论3D-CDFI能提高膀胱肿瘤血流显示率，还可以较准确地判断膀胱肿瘤浸润膀胱壁的深度，对提高膀胱肿瘤检出率和术前分期诊断准确率具有重要的临床价值，同时3D-CDFI检查简便易操作、无创伤、易重复、节时、省费用，患者容易接受，适于临床推广应用。 

Evaluation of the clinical value of 3D-CDFI in bladder tumor diagnose

Objective the purpose of this study is to evaluate clinical value by analyzing 3D-CDFI in bladder tumor diagnose. Methods sampling 52 focuses from 43 patients who had bladder masses from our hospital, from January 2012 to February 2014, comparing diagnosis of two-dimensional (2D) ultrasonographies, 3D-CDFI, three-dimensional (3D) ultrasonographies and cystoscope to result of 3D-CDFI clinical value. Results According to pathological and cystectomy diagnosis, 48 out of 52 bladder masses were bladder tumors. Amongst 48 bladder tumors, 45 cases proved malignant (45/48) while 3 are benign; 4 out of 52 cases are non-48 bladder tumor (3 proved to be clot and 1 proved to endometriosis). Diagnose accordance rate to endometriosis: the accordance rate of result to three-dimensional ultrasound 96.15% (50/52) is higher than two-dimensional ultrasound 85.69% (43/52), P<0.05, which is of statistical significance. The result to Color Doppler ultrasonography 3D-CDFI 85.25% (39/48) within Bladder tumor is higher than CDFI 62.50% (30/48), P<0.05, which is of statistical significance. The accordance rate of result to 3D-CDFI Staging is higher than two-dimensional ultrasound, P<0.05, which is of statistical significance. Conclusion 3D-CDFI can increase the blood flow display rates of bladder tumor, and judge the depth of bladder tumor, so it is important to precise tumor diagnosis. It is feasible for clinical application for 3D-CDFI is easy to control, non-invasive, replicable, time and money saving, and acceptable to patients.